Aarhus University Hospital
Aarhus, 8000, Denmark
NCT Number: NCT03319550
This study compares three different protein supplements (casein, whey and leucine-enriched whey) and their effect on post-inflammatory muscle waste in a model of acute disease. Each test person will undergo all three interventions.
It is believed that leucine is the primary driver of muscle protein synthesis and therefore we hypothesize that leucine-enriched whey and whey are superior to casein in combating post-inflammatory muscle waste, because of its higher leucine content (16%, 11% and 9% leucine, respectively).
Looking for future studies?
Notify Me20 year–40 year
Male
Interventional
Not applicable
Aarhus, 8000, Denmark
Background:
Acute illness is accompanied by infection/inflammation, anorexia and immobilization all contributing to muscle loss, making nutritional supplement optimization an obvious target for investigation and eventually clinical intervention. In the clinical setting large heterogenicity among patients complicates investigations of muscle metabolism during acute illness. Therefore we introduce a disease model by combining "Inflammation + 36 hour fast and bedrest". Inflammation/febrile illness will be initiated by using the well-established "human endotoxemia model" with a bolus injection of Escherichia coli lipopolysaccharide (LPS), known to cause inflammation comparable with the initial phase of sepsis. The amino acid leucine has shown to be particularly anabolic in performance sports, but little is known about its potential beneficial effects during acute illness. Leucine is a powerful activator of muscle protein synthesis and it seems that protein supplements with the highest leucine content elicit a greater increase in protein synthesis than those with a smaller fraction of leucine.
The protein supplements used most in hospitals contain casein derived protein, which has a much lower leucine content than the whey protein compounds typically used in performance sports.
This study compares three different protein supplements.The study is an open, randomized crossover trial. Laboratory technicians, test subjects and investigators will be blinded.
Interventions:
I. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Casein (9% leucine) II. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Whey (11% leucine) III. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Leucine-enriched whey (16% leucine)
The test objects will be given 0,6 g protein/kg, 1/3 as a bolus and 2/3 as sipping over a period of 3,5 hour. Muscle metabolism will be investigated by phenylalanine tracer using the forearm model and total protein metabolism using a carbamide tracer. Through muscle biopsies intracellular signalling pathways will be investigated.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
see experimental description
see experimental description
see experimental description
Time frame: Change from baseline to 3.5 hours after intervention
Changes of muscle phenylalanine net balance (= arterio(phe conc)-venous(phe conc) x flow) from baseline to 3.5 hours after intervention using the forearm model
Time frame: Change from baseline to 3.5 hours after intervention
Changes in whole body protein synthesis rates (umol/kg/h), breakdown rates (umol/kg/h), phenylalanine to tyrosine conversion rates (umol/kg/h) and net balance (umol/kg/h)
Time frame: At baseline and every 30 minutes during the intervention period (3.5 hours)
measures of essential amino acids in the blood
Time frame: At baseline and every 30 minutes during the intervention period (3.5 hours)
Measures of insulin concentration in blood
Time frame: Change from baseline and after 2 hours of intervention
Investigating intracellular activity of muscle metabolism pathways by western blotting.
Time frame: At baseline and after 2.5 hours of intervention
Using indirect calorimetry for 15 min
Time frame: At baseline and after 2.5 hours of intervention
Using indirect calorimetry for 15 min for measuring glucose- (mg/kg/min), fat- (mg/kg/min) and protein oxidation (mg/kg/min)
Time frame: Change from baseline to 3.5 hours after intervention
changes from baseline to 3.5 hours after intervention in Ra(phe)=breakdown (umol/kg/h) and Rd(phe)=synthesis rate (umol/kg/h)
Time frame: Change from baseline and to 1 hour and 3.5 hour after the intervention
Glucagon concentrations in blood
Time frame: Change from baseline and to 1 hour and 3.5 hour after the intervention
GIP concentrations in blood
Time frame: Change from baseline and to 1 hour and 3.5 hour after the intervention
GLP-1 concentrations in blood
Time frame: At baseline and every 30 minutes during the intervention period (3.5 hours)
Glucose concentrations in blood
Time frame: Measured at baseline and 1,2,3,4,5,6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
heart rate (beats/min)
Time frame: Measured at baseline and 1,2,3,4,5,6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
Axillary temperature (celcius)
Time frame: Measured at baseline and 1,2,3,4,5,6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
blood pressure (mmHg)
Time frame: Measured at baseline and 1,2,3,4,5,6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
symptom score (from 0-5) for nausea, back pain, muscle pain, headache and chills. 0=no symptoms, 5=severe symptoms.
Time frame: Measured at baseline and 1, 2, 4, 6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
TNfalfa blood concentrations
Time frame: Measured at baseline and 1, 2, 4, 6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
IL-1 blood concentrations
Time frame: Measured at baseline and 1, 2, 4, 6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
IL-6 blood concentrations
Time frame: Measured at baseline and 1, 2, 4, 6 and 24 hours after LPS (6-8 weeks between visit 1,2 and 3)
IL-10 blood concentrations
University of Aarhus
Other
Whey vs Casein to Combat Post-inflammatory Protein and Muscle Waste - Combining Endotoxemia, Immobilisation and Fasting in Healthy Young Males in a New Model of Acute Febrile Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06769100
Acid-Base Imbalance, Acidosis
Montreal, Quebec, Canada
View Trial DetailsNCT04232254
Behavior, Behavior, Animal
Urbana, Illinois, United States
View Trial DetailsNCT05876299
Muscle Protein Synthesis
Urbana, Illinois, United States
View Trial DetailsNCT06781723
Health, Muscle Protein Synthesis
Urbana, Illinois, United States
View Trial Details